Načítá se...
Adherence to BCR-ABL Inhibitors: Issues for CML Therapy
Treatment for chronic myeloid leukemia (CML) has improved substantially in the last 20 years, especially since the introduction of oral BCR-ABL inhibitors a decade ago. However, for patients to reap the benefits of BCR-ABL inhibitors, they must likely be on therapy for the remainder of their lives....
Uloženo v:
| Vydáno v: | Clin Lymphoma Myeloma Leuk |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2012
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4428159/ https://ncbi.nlm.nih.gov/pubmed/22633166 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2012.04.002 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|